IRIS Accounts Production v25.3.0.601 01468306 Board of Directors 1.4.24 31.3.25 31.3.25 0 0 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh014683062024-03-31014683062025-03-31014683062024-04-012025-03-31014683062023-03-31014683062023-04-012024-03-31014683062024-03-3101468306ns15:EnglandWales2024-04-012025-03-3101468306ns14:PoundSterling2024-04-012025-03-3101468306ns10:Director12024-04-012025-03-3101468306ns10:PrivateLimitedCompanyLtd2024-04-012025-03-3101468306ns10:SmallEntities2024-04-012025-03-3101468306ns10:AuditExempt-NoAccountantsReport2024-04-012025-03-3101468306ns10:SmallCompaniesRegimeForDirectorsReport2024-04-012025-03-3101468306ns10:SmallCompaniesRegimeForAccounts2024-04-012025-03-3101468306ns10:AbridgedAccounts2024-04-012025-03-3101468306ns10:Director22024-04-012025-03-3101468306ns10:CompanySecretary12024-04-012025-03-3101468306ns10:RegisteredOffice2024-04-012025-03-3101468306ns5:CurrentFinancialInstruments2025-03-3101468306ns5:CurrentFinancialInstruments2024-03-3101468306ns5:ShareCapital2025-03-3101468306ns5:ShareCapital2024-03-3101468306ns5:RetainedEarningsAccumulatedLosses2025-03-3101468306ns5:RetainedEarningsAccumulatedLosses2024-03-31
REGISTERED NUMBER: 01468306 (England and Wales)















FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2025

FOR

ALPHACHEM LIMITED

ALPHACHEM LIMITED (REGISTERED NUMBER: 01468306)






CONTENTS OF THE FINANCIAL STATEMENTS
for the year ended 31 March 2025




Page

Company Information 1

Abridged Balance Sheet 2

Notes to the Financial Statements 3


ALPHACHEM LIMITED

COMPANY INFORMATION
for the year ended 31 March 2025







DIRECTORS: M N Bharwani BPharm MRPS
Mrs G K Bharwani





SECRETARY: M N Bharwani BPharm MRPS





REGISTERED OFFICE: 51 Castlemaine Avenue
South Croydon
Surrey
CR2 7HW





REGISTERED NUMBER: 01468306 (England and Wales)






ALPHACHEM LIMITED (REGISTERED NUMBER: 01468306)

ABRIDGED BALANCE SHEET
31 March 2025

2025 2024
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 6,976,032 6,973,772
Investments 5 1,653,201 1,653,201
8,629,233 8,626,973

CURRENT ASSETS
Debtors 80,517 141,056
Investments 170 170
Cash at bank 62,609 146,945
143,296 288,171
CREDITORS
Amounts falling due within one year 3,501,028 4,039,251
NET CURRENT LIABILITIES (3,357,732 ) (3,751,080 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

5,271,501

4,875,893

CAPITAL AND RESERVES
Called up share capital 50,000 50,000
Retained earnings 5,221,501 4,825,893
5,271,501 4,875,893

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

All the members have consented to the preparation of an abridged Income Statement and an abridged Balance Sheet for the year ended 31 March 2025 in accordance with Section 444(2A) of the Companies Act 2006.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 12 December 2025 and were signed on its behalf by:





M N Bharwani BPharm MRPS - Director


ALPHACHEM LIMITED (REGISTERED NUMBER: 01468306)

NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 March 2025

1. STATUTORY INFORMATION

Alphachem Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The financial statements are prepared in UK Pound Sterling, which is the functional currency of the company.

Tangible fixed assets
Land and buildings is initially measured at cost on acquisition and subsequently at fair value as at each
accounts date. Changes in fair value are recognised in the income statement. Deferred taxation is provided on these gains at the rate expected to apply when the property is sold and charged to the profit and loss account.

Fixtures and fittings are stated at historical cost less accumulated depreciation and accumulated impairment losses.

Depreciation is recognised to write off the cost of assets less their residual values over their useful lives, using the reducing balance methods.

Fixtures & fittings 25% reducing balance

At each reporting date fixed assets are reviewed to determine whether there is any indication that those assets have suffered an impairment loss. If there is an indication of possible impairment, the recoverable amount of any affected asset is estimated and compared with its carrying amount. If the estimated recoverable amount is lower, the carrying amount is reduced to its estimated recoverable amount, and an impairment loss is recognised immediately in the income statement.

If an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but not in excess of the amount that would have been determined had no impairment loss been recognised for the asset in prior years. A reversal of an impairment loss is recognised immediately in the income statement.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2024 - NIL).

ALPHACHEM LIMITED (REGISTERED NUMBER: 01468306)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 31 March 2025

4. TANGIBLE FIXED ASSETS
Totals
£   
COST
At 1 April 2024 8,068,228
Additions 4,290
At 31 March 2025 8,072,518
DEPRECIATION
At 1 April 2024 1,094,456
Charge for year 2,030
At 31 March 2025 1,096,486
NET BOOK VALUE
At 31 March 2025 6,976,032
At 31 March 2024 6,973,772

5. FIXED ASSET INVESTMENTS

Information on investments other than loans is as follows:
Totals
£   
COST
At 1 April 2024
and 31 March 2025 1,653,201
NET BOOK VALUE
At 31 March 2025 1,653,201
At 31 March 2024 1,653,201